DPP-4 inhibitors
Dipeptidyl Peptidase 4 Inhibitors and Inflammation: Dpp 4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level
... dase-4 inhibitors (40 sitagliptin and 40 vildagliptin) to their ongoing thera- ...with DPP-4 inhibitors was 18 (2 - 64) ...before DPP-4 inhibitors and it was ...
12
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
... a DPP-4 inhibitor which has shown good clinical effect in reducing glycemia both as monotherapy and in combination with other oral agents and with ...with DPP-4 inhibitors and metformin ...
11
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
... of DPP-4 inhibitors has increased and DPP-4 inhibitors have developed into an important drug ...class. DPP-4 inhibitors act by increasing endogenous GLP-1 ...
9
Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
... (DPP-4) inhibitors modulate insulin and glucagon secretion in a glucose-dependent manner, and consequently a low propensity of hypoglycemia has consistently been reported across dif- ferent patient ...
10
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
... and DPP-4 Inhibitors There are numerous factors to consider when selecting among the treatment options for type 2 diabetes, including the five incretin-based ...
10
Alogliptin: a new addition to the class of DPP-4 inhibitors
... At this time, there is a lack of long-term safety data for alogliptin and other DPP-4 inhibitors, especially those related to generalized DPP-4 inhibition. Studies of longer duration ...
10
Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
... peptidase 4 (DPP-4) inhibitors are newer anti-diabetic agents which have shown to well maintain blood glucose level over the long-term (decent glycated hemoglobin [HbA1c]), and were not ...
9
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
... some DPP-4 inhibitors and HF will require additional trials and potentially more ...the DPP-4 class effects on biomarkers, which propagates through to our final event rate ...of ...
11
Synthesis of new DPP 4 inhibitors based on a novel tricyclic scaffold
... As the synthesis of the scaffolds 9a and 9b was in race- mic form, the separation of the diastereoisomers of com- pounds 2a and 2b was required. Rewardingly, both dia- stereomers proved separable under chiral HPLC condi- ...
7
Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins
... with inhibitors of DPP- ...this DPP-4 inhibitor did not provide any cardioprotective benefit [65, ...with DPP-4 in- hibitors compared with placebo/active control without any ...
16
Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
... (DPP-4) inhibitors have demonstrated lower risk of hypogly- cemia during Ramadan fasting, with better patient ...of DPP-4 inhibitors (such as vildagliptin) during Ramadan fasting ...
5
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
... able DPP-4 inhibitors, also known as ‘gliptins’ (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin), are small molecules used orally with similar overall clinical efficacy and safety ...
13
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
... reduction in triglyceride and free fatty acid levels could be a consequence of the elevation of active GLP-1 and insu- lin levels. Furthermore, in Zucker fatty rats, the repeated administration of teneligliptin for 2 ...
9
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
... For monotherapy in Asian countries, all of the three agents are demonstrated to be effective and safe compar- ing with placebo [21-23]. When it comes to combination therapy, the three agents demonstrated great glycemic ...
9
Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus
... DPP-4 inhibitors could have a beneficial effect not only on blood glucose levels but also on blood pressure and artery ...the DPP-4i observed therapy benefit might be due to lifestyle changes ...
7
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
... (DPP-4) inhibitors are antidiabetic agents that pre- dominantly reduce postprandial plasma glucose ...levels. DPP-4 inhibitors are associated with fewer gastrointestinal side ...
19
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
... a DPP-4 ...of DPP-4 inhibitors, though there had been no direct comparison of the effects of DPP-4 inhibitors on FABP4 ...
10
Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines
... of DPP-4 also potentiates the stem cell chemokine, stromal cell-derived factor-1 (SDF-1), which can promote inflammation, proliferative responses and ...However, DPP-4 inhibitors have ...
8
Review Article Combined use of dipeptidyl peptidase-4 inhibitors and metformin reduces blood sugar level and improves pancreatic islet β cell function in the treatment of type 2 diabetes mellitus: a meta-analysis
... of DPP-4 inhibitors and MET was better than that of MET alone in reducing ...of DPP-4 inhibitors and MET had better efficacy than MET alone in improving pancreatic islet β cell ...
9
Original Article Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis
... of DPP-4 inhibitors in combination with insulin has been proposed as an alternative therapeutic option for poorly controlled type 2 diabetes (T2D) ...of DPP-4 inhibitor and insulin is ...
10